personalized

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

...ingAeroLEF(TM), patients can identify and select a personalized dosefor each pain episode, achieving both rapid onset and extendedduration of analgesia. About YM BioSciences YM BioSciences Inc. is an oncology company that identifies,develops and commercializes differentiated products for patientsworldwide. The ...

Researchers Discover Method for Identifying How Cancer Evades the Immune System

...ncer. “I see it as the beginning stages of personalized medicine,where we develop tactics for treating the unique genetic make-up ofa specific tumor,” Epstein said. “It becomes even morenecessary when we look at all the immunotherapies that are becomingavailable or are beginning to emerge from...

Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo

...aceutical company working to advance thescience of personalized medicine to improve the lives of patientswith various CNS disorders, including insomnia and schizophrenia.The company has three product candidates in clinical development.Vanda's lead product candidate, iloperidone, is a compound for thetreatment of ...

ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO

...of patients prior to treatmentallows for optimized personalized dosing and improved drugtolerance. Patients with ...sults were a significant stepin the development of personalized medicines. “The data thatDr Kuhn presented today show very clearly that we now understandthe e...

ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO

...Kuhn. "Weare excited by the new opportunities that personalized dosing ofQuinamed offers for a range of solid tumo...of patients prior to treatmentallows for optimized personalized dosing and improved drugtolerance. -- Patients with rapid and intermediate acetylator genotypes(who...

Antipsychotic Iloperidone Results Show Favorable Akathisia Profile

...aceutical company working toadvance the science of personalized medicine. "Many people who have akathisia will sa...aceutical company working to advance thescience of personalized medicine to improve the lives of patientswith schizophrenia. The company has three product candidate...

Argos Therapeutics Presents Immunosuppression Data for Soluble CD83 at the American Society of Transplantation Congress 2007

...ures of a patient's disease. This newgeneration of personalized cancer and infectious diseasetherapeutics, created using the Company's "Arcelis" technology,trains the immune system to recognize and attack the disease.Argos' scientific leadership in RNA-loaded dendritic cells andadvanced manufacturing processes pr...

YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain

...esigned to enable patients toidentify and select a personalized dose for each pain episode,achieving both rapid onset and extended duration of analgesia. The trial evaluated the SPRID4 for AeroLEF(TM) compared withplacebo for the treatment of the first pain episode. SPRID4 is asummary of the combined changes i...

Researchers Identify New Genetic Risk Factors for Type 2 Diabetes

...quo;Such research is opening the door tothe era of personalized medicine. Our current one-size-fits-allapproach will soon give way to more individualized strategies basedon each person’s unique genetic make-up.” Led by Michael Boehnke, Ph.D., of the University ofMichigan’s School of Public...

Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection

...VELCADE. "Millennium is recognized as a leader in personalized medicine,and this publication is a testament to the strength of our clinicalinnovation," said Nancy Simonian, M.D., Chief Medical Officer,Millennium. "The genomic findings add further knowledge aboutVELCADE efficacy in treating a broad range of multi...

AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles

... This targeted approach isan additional example of personalized therapy which is becomingmore and more the way of the future," said Dr. Jurgen Engel,Executive Vice President, Global R&D and COO of AEternaZentaris. About AEterna Zentaris Inc. AEterna Zentaris Inc. is a global, pure play biopharmaceuticalcomp...

ACC Presentation Indicates Interleukin-1 Gene Variants Determine Increased Risk for Coronary Artery Disease from Oxidized Phospholipids

...cused on developing, acquiring,and commercializing personalized health products that can helpindividuals improve a...ements regarding our ability to developdiagnostic, personalized nutritional and therapeutic products toprevent or treat diseases of inflammation and other geneticva...